D.E. Shaw & Co’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-186,853
| Closed | -$7.52M | – | 4862 |
|
|
2026
Q1 | $7.52M | Sell |
186,853
-262,823
| -58% | -$5.66M | ﹤0.01% | 1857 |
|
|
2025
Q4 | $11.3M | Sell |
449,676
-7,115
| -2% | -$167K | 0.01% | 1647 |
|
|
2025
Q3 | $10.3M | Buy |
456,791
+205,722
| +82% | +$4.8M | 0.01% | 1659 |
|
|
2025
Q2 | $4.35M | Buy |
+251,069
| New | +$4.65M | ﹤0.01% | 2133 |
|
|
2025
Q1 | – | Sell |
-20,000
| Closed | -$553K | – | 4233 |
|
|
2024
Q4 | $638K | Buy |
+20,000
| New | +$601K | ﹤0.01% | 3466 |
|
|
2024
Q1 | – | Sell |
-33,086
| Closed | -$2.11M | – | 4322 |
|
|
2023
Q4 | $1.98M | Sell |
33,086
-6,387
| -16% | -$324K | ﹤0.01% | 2671 |
|
|
2023
Q3 | $1.5M | Sell |
39,473
-488,338
| -93% | -$21.5M | ﹤0.01% | 2804 |
|
|
2023
Q2 | $48.1M | Buy |
527,811
+114,958
| +28% | +$9.92M | 0.05% | 449 |
|
|
2023
Q1 | $27.2M | Buy |
412,853
+399,955
| +3,101% | +$23.1M | 0.03% | 711 |
|
|
2022
Q4 | $667K | Sell |
12,898
-184,466
| -93% | -$9.78M | ﹤0.01% | 3697 |
|
|
2022
Q3 | $13.5M | Buy |
197,364
+192,794
| +4,219% | +$11.4M | 0.02% | 1116 |
|
|
2022
Q2 | $207K | Sell |
4,570
-28,464
| -86% | -$1.3M | ﹤0.01% | 4533 |
|
|
2022
Q1 | $1.68M | Sell |
33,034
-4,856
| -13% | -$214K | ﹤0.01% | 3475 |
|
|
2021
Q4 | $1.79M | Sell |
37,890
-37,632
| -50% | -$1.48M | ﹤0.01% | 3452 |
|
|
2021
Q3 | $2.49M | Sell |
75,522
-169,507
| -69% | -$9.52M | ﹤0.01% | 2831 |
|
|
2021
Q2 | $15.5M | Sell |
245,029
-91,614
| -27% | -$4.73M | 0.01% | 1164 |
|
|
2021
Q1 | $14.4M | Sell |
336,643
-77,419
| -19% | -$3.66M | 0.01% | 1134 |
|
|
2020
Q4 | $23.7M | Buy |
414,062
+28,196
| +7% | +$1.19M | 0.02% | 869 |
|
|
2020
Q3 | $11.6M | Sell |
385,866
-145,895
| -27% | -$4.36M | 0.01% | 1146 |
|
|
2020
Q2 | $17.4M | Buy |
531,761
+162,028
| +44% | +$5.2M | 0.02% | 860 |
|
|
2020
Q1 | $9.9M | Buy |
369,733
+221,326
| +149% | +$7.86M | 0.02% | 1001 |
|
|
2019
Q4 | $4.54M | Buy |
148,407
+137,342
| +1,241% | +$3.8M | 0.01% | 1806 |
|
|
2019
Q3 | $267K | Buy |
+11,065
| New | +$305K | ﹤0.01% | 3513 |
|
Other funds holding APLS
D.E. Shaw & Co's APLS Position: Q2 2026 in Review
D.E. Shaw & Co sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 186,853 shares — an estimated $7.52M sold.
D.E. Shaw & Co first reported a position in APLS in Q3 2019 and held it in 23 quarters. The position peaked at $48.1M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- D.E. Shaw & Co reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- D.E. Shaw & Co sold 186,853 Apellis Pharmaceuticals shares in Q2 2026, an estimated $7.52M.
- D.E. Shaw & Co first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 23 quarters.
- D.E. Shaw & Co's Apellis Pharmaceuticals position peaked at $48.1M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.